Nkarta Inc. (NKTX)
1.76
-0.15 (-7.85%)
At close: Apr 03, 2025, 1:54 PM
-7.85% (1D)
| Bid | 1.76 |
| Market Cap | 125.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.6 |
| PE Ratio (ttm) | -1.1 |
| Forward PE | -1.27 |
| Analyst | Buy |
| Ask | 1.77 |
| Volume | 714,448 |
| Avg. Volume (20D) | 1,503,806 |
| Open | 1.80 |
| Previous Close | 1.91 |
| Day's Range | 1.73 - 1.83 |
| 52-Week Range | 1.31 - 10.16 |
| Beta | 0.90 |
About NKTX
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 157
Stock Exchange NASDAQ
Ticker Symbol NKTX
Website https://www.nkartatx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for NKTX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 806.52% from the latest price.
Stock Forecasts1 week ago
+43.8%
Nkarta shares are trading higher after the company...
Unlock content with
Pro Subscription
7 months ago
+3.22%
Nkarta shares are trading higher after the company reported better-than-expected Q2 EPS results. Also, Raymond James upgraded the stock from Outperform to Strong Buy.
